NuvOx Therapeutics' IPO
Filed Jul 17, 2026 (Form S-1). No terms yet. Applied to list on NYSE American as NUOX.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
Once NuvOx Therapeutics lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does NuvOx Therapeutics do?
“We are a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role.”
| Fact | NuvOx Therapeutics |
|---|---|
| Website | nuvoxtherapeutics.com |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | NuvOx Therapeutics |
|---|---|
| Shares offered | 2,860,000 |
| Net proceeds the company expects | About $17.4 million |
| Underwriters' option | 429,000 more shares |
| Underwriter | ThinkEquity |
| Exchange | NYSE American, as NUOX (applied to list) |
| Shares outstanding after | 13,339,579 |
What the filing says about its money
| Fact | NuvOx Therapeutics |
|---|---|
| Grant revenue | $975,000, year to December 31, 2025 |
| Net loss | $16.6 million, year to December 31, 2025 |
| Last preferred stock | Series A preferred |
What risks does NuvOx Therapeutics name first?
- “We are a development-stage company with a limited operating history.”
- “We have no products approved for commercial sales and a limited operating history upon which to evaluate our ability to commercialize our product candidate.”
- “We have a history of operating losses and expect to continue to incur substantial losses for the foreseeable future.”
Every date of NuvOx Therapeutics' IPO
| What | Day |
|---|---|
| Registration filed | Jul 17, 2026 |
| Lock-up | 6 months |
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
NuvOx Therapeutics IPO questions
When is NuvOx Therapeutics' IPO?
Filed Jul 17, 2026 (Form S-1). No terms yet. Applied to list on NYSE American as NUOX.
What is NuvOx Therapeutics' IPO price?
NuvOx Therapeutics has not set a price range yet; its amended S-1 of Oct 13, 2026 leaves it blank.
How many shares is NuvOx Therapeutics selling?
2,860,000 shares, and the underwriters may buy 429,000 more, per its amended S-1.
Who are the underwriters?
ThinkEquity, as the prospectus's cover names them.
When does the lock-up end?
Its prospectus sets a lock-up of 6 months; the day it ends is read from its final prospectus once it lists.
Does Breakaway rate NuvOx Therapeutics?
Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.
Can Breakaway say where NuvOx Therapeutics' price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Once NuvOx Therapeutics lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.